Abstract

Background and Aims: The goal of dyslipidemia therapy is the prevention of atherothrombotic disease (ATD) or if ATD is extant then prevention of future clinical ATD events. Plaque regression/stabilization has been shown to correlate with more favorable ATD outcomes and plaque progression to correlate with worse ATD outcomes. In this presentation the author exanmines eight published angiographic regression trials in terms of end-of-trial lipids and angiographic outcomes.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.